Drug · DIN 02255758
RISPERDAL CONSTA
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 8, 2004; first marketed September 8, 2004.
- Drug Identification Number (DIN)
- 02255758
- Company (DIN owner)
- Janssen Inc.Toronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Kit; Powder For Suspension (Sustained-Release
- Route
- Intramuscular
- Therapeutic class (ATC)
- Risperidone N05AX08
- Class
- Human
- Record last updated
- June 23, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RISPERIDONE | 50 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 16, 2004: NOC 4799Supplement to a New Drug Submission (SNDS) · New dosage form: powder for injectable prolonged-release suspension
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “risperdal”. A notice may cover another product or only some lots: read it to see what it covers.
Other DINs named RISPERDAL CONSTA
- DIN 02255707 · Marketed
- DIN 02255723 · Marketed
- DIN 02298465 · Marketed